CareDx Inc (CDNA)

NASDAQ: CDNA · Real-Time Price · USD

15.06

-1.82 (-10.78%)

At close: May 01, 2025, 3:59 PM

15.34

1.83%

After-hours: May 01, 2025, 05:21 PM EDT

-10.78% (1D)

Bid	14.9
Market Cap	837.56M
Revenue (ttm)	346.42M
Net Income (ttm)	58.85M
EPS (ttm)	0.93
PE Ratio (ttm)	16.2
Forward PE	-845
Analyst	Buy

Ask	15.34
Volume	2,606,716
Avg. Volume (20D)	921,489.6
Open	16.81
Previous Close	16.88
Day's Range	14.86 - 17.14
52-Week Range	8.96 - 34.84
Beta	2.18

About CDNA

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The co...

Sector Healthcare

IPO Date Jul 17, 2014

Employees 644

Stock Exchange NASDAQ

Ticker Symbol CDNA

Website https://www.caredx.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 92.50% from the latest price.

Stock Forecasts

Earnings Surprise

New

CareDx Inc has released their quartely earnings on Apr 30, 2025:

Revenue of $84.69M exceeds estimates by $155K, with 17.54% YoY growth.

EPS of 0.09 exceeds estimates by 0.02, with 400.00% YoY growth.

Why Price Moved

2 months ago

+11.16%

CareDx shares are trading higher after Chevy Chase... Unlock content with Pro Subscription

6 months ago

-15.84%

CareDx shares are trading lower. The company reported preliminary Q3 financial results.

News

2 days ago · seekingalpha.com

CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President & Chief Executive Officer Robert ...

2 days ago · zacks.com

CareDx (CDNA) Tops Q1 Earnings Estimates

CareDx (CDNA) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.03 per share a year ago.

1 week ago · businesswire.com

CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

1 week ago · businesswire.com

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ (“CareDx” or the “Company”)— a leading precision medicine company focused on the discovery, development, and co...

3 weeks ago · businesswire.com

CareDx to Report First Quarter 2025 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...

1 month ago · businesswire.com

CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its...

1 month ago · businesswire.com

CareDx Launches Two Expanded Indications for AlloSure Testing Services

2 months ago · zacks.com

New Strong Buy Stocks for February 27th

BCS, CDNA, PGR, EZPW and EVER have been added to the Zacks Rank #1 (Strong Buy) List on February 27, 2025.

2 months ago · seekingalpha.com

CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Ab...

2 months ago · zacks.com

CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stree...

Load More News